Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.55 |
| ▸ | CD44 | P16070 | 2/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403997 | 0.85 | PRCP (0.75) | PRCPCD44IRAK4PNMTMAOB | |
| SCHEMBL29419338 | 0.85 | PRCP (0.75) | PRCPCD44IRAK4PNMTMAOB | |
| SCHEMBL1011319 | 0.83 | PRCP (0.51) | PRCPCD44IRAK4PARP10PARP11 | |
| SCHEMBL30519159 | 0.80 | PRCP (0.51) | PRCPCD44IRAK4PNMTMAOB | |
| SCHEMBL17021262 | 0.80 | PRCP (0.51) | PRCPCD44IRAK4PNMTMAOB | |
| Hydrochloric Acid SCHEMBL29893369 | 0.79 | PRCP (0.50) | PRCPCD44IRAK4CD274SCN9A | |
| SCHEMBL21744607 | 0.79 | CD44 (0.46) | PRCPCD44PKN2IRAK4PNMT | |
| Hydrochloric Acid SCHEMBL27077371 | 0.79 | PRCP (0.50) | PRCPCD44IRAK4CD274SCN9A | |
| SCHEMBL5880546 | 0.78 | CD44 (0.56) | PRCPCD44IRAK4PNMTMAOB | |
| SCHEMBL5692082 | 0.76 | NPY5R (0.47) | PRCPMAOBCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-20 | — | — | US | disclosed |
| EP-2899183-B1 | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725435-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| CN-103987696-B | Substituted tetrahydro isoquinoline compound as factor XI, plasma thromboplastin antecedent A inhibitor | 百时美施贵宝公司 | 2016-12-21 | — | — | CN | disclosed |
| US-20160289209-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-9394276-B2 | Substituted 1,2,3,4-tetrahydro-2,6-naphthyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2766347-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | F12, TFPI, F11 | PRCP 95/4885CD44 4689/4885PKN2 210/4885 |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | PRCP 220/4885CD44 4844/4885PKN2 238/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | PRCP 167/4885CD44 4686/4885PKN2 393/4885 |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | PRCP 220/4885CD44 4844/4885PKN2 238/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | PRCP 2427/4885CD44 4881/4885PKN2 675/4885 |
| US-20160289209-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | PRCP 220/4885CD44 4844/4885PKN2 238/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | PRCP 2221/4885CD44 4484/4885PKN2 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.